Articles From: The New Ireland Fund, Inc. Announces Managed Distribution Policy and Results of Annual Meeting to Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar Safety and Efficacy Profile to Lantus®


http://media.marketwire.com/attachments/201302/123939_IRL.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1123833&ProfileId=051205&sourceType=1 BOSTON, MA --
Sign-up for The New Ireland Fund, Inc. Announces Managed Distribution Policy and Results of Annual Meeting investment picks
Veristat, a full service Contract Research Organization, announced today that Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, has entered into a Preferred Provider agreement with Veristat.
Sign-up for Veristat and Karyopharm Therapeutics Inc. Enter into Preferred Provider Agreement for Oncology and Novel Therapeutic Advancement investment picks
Access Midstream Partners, L.P. (NYSE:ACMP) (the “Partnership”) today confirmed that Williams Companies, Inc. (“Williams”) announced it had entered into an agreement to acquire all of the interests in both Access Midstream Partners, L.P. (the “Partnership”) and the Partnership’s general partner, Access Midstream Partners GP, L.L.C, currently owned by Global Infrastructure Partners II (“GIP”). If this transaction is completed, Williams will own and control the Partnership’s general partner and GIP will no longer have any ownership interest in the Partnership or its general partner.
Sign-up for Access Midstream Partners, L.P. Confirms Williams Announcement of Planned Acquisition from GIP and Proposal for Williams Partners L.P. to Merge with Access Midstream Partners, L.P. investment picks
Williams Partners L.P. (NYSE:WPZ) advised its unitholders to reference news issued today by its general partner Williams (NYSE:WMB). The partnership’s general partner, Williams, today announced a proposal for Williams Partners to merge with and into Access Midstream Partners L.P. (NYSE:ACMP). As well, Williams Partners today updated its 2014 financial guidance.
Sign-up for Williams Partners Advises Unitholders to Reference News Today From Its General Partner, Williams (NYSE:WMB); Updates 2014 Financial Guidance investment picks
--Only Rentrak Provides the Global Standard in Box Office Reporting--
Sign-up for Rentrak Announces Worldwide Box Office Results for Weekend of June 15, 2014 investment picks
Williams (NYSE:WMB) today announced that it has agreed to acquire the 50 percent general partner interest and 55.1 million limited partner units in Oklahoma City-based Access Midstream Partners L.P. (NYSE:ACMP) held by Global Infrastructure Partners II (“GIP”) for $5.995 billion in cash.
Sign-up for Williams Agrees to Acquire Global Infrastructure Partners’ GP and LP Interests in Access Midstream Partners for $5.995 Billion; Plans Higher Dividend; Proposes Subsequent Merger of Access Midstream Partners and Williams Partners investment picks
- For those taking metformin, empagliflozin/linagliptin combination tablet showed statistically significant reductions in blood glucose vs.
Sign-up for Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials investment picks
CONSISTENT 1 Trial Results Presented in Late-Breaker Poster SAN DIEGO , June 15, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented a scientific poster highlighting the CONSISTENT 1 trial results at the 74th Scientific Sessions of the American Diabetes Association in San Francisco .
Sign-up for Halozyme Announces Presentation Of Clinical Data At The American Diabetes Association 74th Scientific Sessions investment picks
2014/6/15
The Board of Directors of Orbotech Ltd.
Sign-up for Orbotech Responds to Ion’s Requests and Proposes to Declassify the Board of Directors investment picks
2014/6/15
Clara's Big Ride for Bell Let's Talk returns to Ontario June 16, en route to Canada Day celebrations in Ottawa Canada NewsWire WINNIPEG , June 15, 2014 /CNW/ - Starting tomorrow and for the next 2 weeks, Canadian Olympian Clara Hughes brings the Big Ride for Bell Let's Talk to communities across Northern Ontario .
Sign-up for Clara's Big Ride for Bell Let's Talk returns to Ontario June 16, en route to Canada Day celebrations in Ottawa investment picks
Limelight Networks (Nasdaq:LLNW), a global leader in digital content delivery, today announced that it has received an unsolicited offer to purchase the company from an entity that management believes is a non-credible source.
Sign-up for Limelight Network Receives Unsolicited Offer to Purchase from Questionable Source investment picks
Oshkosh Defense , a division of Oshkosh Corporation (NYSE: OSK), will participate in daily live demonstrations at Eurosatory 2014 to showcase the company’s TerraMax ® Unmanned Ground Vehicle (UGV) technology.
Sign-up for Oshkosh Defense Demonstrates Autonomous Route Clearance Mission Capability at Eurosatory 2014 investment picks
2014/6/15
By William L.
Sign-up for UPDATE: Why stock buybacks are losing their fizz investment picks
2014/6/15
HONG KONG , June 15, 2014 /PRNewswire/ -- Anton Oilfield Services Group ("Antonoil" or the "Group", HKEx stock code: 3337), the leading independent oilfield services provider in China , is pleased to announce that as at June 13 , the Group's production line for ceramic proppants, a critical fracturing material, has been operating smoothly for two months, a testament of the stability and reliability of this production line's operation and the quality of its product.
Sign-up for Antonoil's Ceramic Proppant Production Line in Smooth Operation for Two Months investment picks
By Sue Chang, MarketWatch SAN FRANCISCO (MarketWatch) -- Among the companies whose shares are expected to see active trading in Monday's session are Layne Christensen Co.
Sign-up for UPDATE: Layne Christensen, Korn/Ferry are stocks to watch investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G017035-001&sourceType=1 NEW YORK , NY--(Marketwired - June 15, 2014) - JetBlue Airways (NASDAQ: JBLU), today launches its take on premium service, Mint, between New York (JFK) and Los Angeles (LAX). By August 3, 2014, all JetBlue flights between New York (JFK) and Los Angeles (LAX) will feature Mint.
Sign-up for JetBlue's Premium Transcontinental Service Mint Takes Off investment picks
2014/6/15
WestJet makes first scheduled transatlantic flight Canada NewsWire Airline launches same-plane service from Toronto to Dublin tonight CALGARY , June 15, 2014 /CNW/ - WestJet marks a key milestone in its 18-year history tonight with the launch of its first scheduled transatlantic service between Toronto and Dublin, Ireland , with a brief stop in St.
Sign-up for WestJet makes first scheduled transatlantic flight investment picks
http://media.marketwire.com/attachments/201007/9697_Lithia-Logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1123796&ProfileId=051205&sourceType=1 MEDFORD, OR --
Sign-up for Lithia Motors and DCH Auto Group USA Combine to Create National Group investment picks
New variant guided successfully to target with laser PARIS , June 15, 2014 /PRNewswire/ -- In a company-funded R&D initiative, Raytheon Company (NYSE: RTN) successfully fired the dual-mode GPS- and laser-guided Excalibur S for the first time.
Sign-up for Raytheon conducts first live fire test of Excalibur S investment picks
2014/6/14
By Charles Passy, MarketWatch How about a tall, cold glass of fish guts?
Sign-up for UPDATE: 5 surprising ingredients in your favorite beer investment picks
2014/6/14
By Catey Hill, MarketWatch , Quentin Fottrell Some American workers may finally see an increase in their salary, according to a report in "The Wall Street Journal," as several companies --
Sign-up for UPDATE: 5 reasons you are poor investment picks
2014/6/14
Sanofi's Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering Than Liraglutide When Both Were Added to Insulin Glargine Canada NewsWire PARIS , June 14, 2014 /CNW/ - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia ® (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide, showing a significantly more pronounced post-prandial (after-meal) glucose (blood sugar) lowering effect after a test-meal than liraglutide when both were added to optimally titrated Lantus ® (insulin glargine). Lowering of post-prandial glucose was measured as change from baseline in incremental area under the glucose curve for 4 hours after a standardized solid breakfast, at week 8.
Sign-up for Sanofi's Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering Than Liraglutide When Both Were Added to Insulin Glargine investment picks
2014/6/14
Sanofi Announces Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) in Japanese People with Uncontrolled Diabetes Canada NewsWire - In EDITION JP I and II, investigational Toujeo ® demonstrated similar blood sugar control with fewer night-time low blood sugar events over 6-month study period, vs.
Sign-up for Sanofi Announces Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) in Japanese People with Uncontrolled Diabetes investment picks
Results from Clinical Study in Type 2 Diabetes Patients with Renal Impairment and Preclinical Study in Type 1 Diabetes THE WOODLANDS, Texas , June 14, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) , presented data at the 74 th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco on LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) that is designed to lower blood glucose levels through two insulin-independent mechanisms of action.
Sign-up for Lexicon Presents LX4211 Data at American Diabetes Association Meeting investment picks
2014/6/14
Sanofi Reports Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) Toujeo ® is the intended trade name for insulin glargine [rDNA origin] injection, 300 U/mL; formerly abbreviated as "U300". U300 is not currently approved or licensed anywhere in the world.
Sign-up for Sanofi Reports Positive Phase 3 Results for Toujeo(R) investment picks
NEW YORK, June 14, 2014 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announces that it has filed a class action lawsuit on behalf of purchasers of Ocean Power Technologies, Inc. (Nasdaq:OPTT) securities during the period from January 14, 2014 to June 9, 2014 inclusive, seeking to recover damages for violations of the federal securities laws.
Sign-up for The Rosen Law Firm Files Securities Fraud Class Action Against Ocean Power Technologies, Inc. -- OPTT investment picks
2014/6/14
-- Real World Outcome Study of Patients with Type 2 Diabetes Presented at American Diabetes Association 74th Scientific Sessions --
Sign-up for Patients Continuing On Sanofi's Lantus® Had Lower Blood Sugar Levels Than Those who Switched to Insulin Detemir investment picks
2014/6/14
- Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases in risk of low blood sugar events of up to 31% at night-time compared with Lantus® - - All studies in the phase 3 "EDITION" clinical trial program, including a study with type 1 patients, met their primary endpoint - - Toujeo dossier accepted by the EMA - PARIS , June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that, in a pooled analysis, investigational therapy Toujeo ® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia) at any time of day, including night-time events, compared with Lantus ® (insulin glargine [rDNA origin] injection, 100 U/mL). The pooled analysis comprised data from three differing type 2 patient populations.
Sign-up for Sanofi Reports Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) investment picks
2014/6/14
PARIS , June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia ® (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide, showing a significantly more pronounced post-prandial (after-meal) glucose (blood sugar) lowering effect after a test-meal than liraglutide when both were added to optimally titrated Lantus ® (insulin glargine). Lowering of post-prandial glucose was measured as change from baseline in incremental area under the glucose curve for 4 hours after a standardized solid breakfast, at week 8.
Sign-up for Sanofi's Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering than Liraglutide when Both were Added to Insulin Glargine investment picks
Companies present comprehensive data for LY2963016, investigational new insulin glargine product SAN FRANCISCO , June 14, 2014 /PRNewswire/ -- For the first time today, Eli Lilly and Company (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals Inc. presented data showing that LY2963016, the alliance's investigational new insulin glargine product, has a similar safety and efficacy profile to currently marketed insulin glargine (Lantus ® ). 1,2,3,4,5,6 Results from these Phase I and Phase III studies were presented at the 74 th American Diabetes Association Scientific Sessions in San Francisco .
Sign-up for Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar Safety and Efficacy Profile to Lantus® investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: The New Ireland Fund, Inc. Announces Managed Distribution Policy and Results of Annual Meeting to Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar Safety and Efficacy Profile to Lantus®
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices